{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:56:05Z","timestamp":1790650565635,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01124-5","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:02:32Z","timestamp":1724756552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-4442","authenticated-orcid":false,"given":"Baoyan","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian F.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vod\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-2050","authenticated-orcid":false,"given":"Sigve","family":"Nakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-7503","authenticated-orcid":false,"given":"Ankush","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvild Nuvin","family":"Blaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Brodtkorb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Tr\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-3223","authenticated-orcid":false,"given":"Ola","family":"Myklebost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-6131","authenticated-orcid":false,"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-8804","authenticated-orcid":false,"given":"Qiang","family":"Pan-Hammarstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9 B.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Meza-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9103-1077","authenticated-orcid":false,"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-4912","authenticated-orcid":false,"given":"Ole Christian","family":"Lingj\u00e6rde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0394-9986","authenticated-orcid":false,"given":"June Helen","family":"Myklebust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1124_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"1124_CR2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575\u201382.","journal-title":"J Clin Oncol"},{"key":"1124_CR3","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272\u20138.","journal-title":"J Clin Oncol"},{"key":"1124_CR4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1084\/jem.20061292","volume":"203","author":"S Roulland","year":"2006","unstructured":"Roulland S, Navarro JM, Grenot P, Milili M, Agopian J, Montpellier B, et al. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J Exp Med. 2006;203:2425\u201331.","journal-title":"J Exp Med"},{"key":"1124_CR5","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1200\/JCO.2013.52.8190","volume":"32","author":"S Roulland","year":"2014","unstructured":"Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, et al. t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32:1347\u201355.","journal-title":"J Clin Oncol"},{"key":"1124_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298\u2013303.","journal-title":"Nature"},{"key":"1124_CR7","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C B\u00f6d\u00f6r","year":"2013","unstructured":"B\u00f6d\u00f6r C, Grossmann V, Popov N, Okosun J, O\u2019Riain C, Tan K, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122:3165\u20138.","journal-title":"Blood"},{"key":"1124_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176\u201381.","journal-title":"Nat Genet"},{"key":"1124_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes A-\u00c1, et al. Genetics of Follicular Lymphoma Transformation. Cell Rep. 2014;6:130\u201340.","journal-title":"Cell Rep"},{"key":"1124_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129:473\u201383.","journal-title":"Blood"},{"key":"1124_CR11","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","volume":"121","author":"MR Green","year":"2013","unstructured":"Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121:1604\u201311.","journal-title":"Blood"},{"key":"1124_CR12","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","volume":"112","author":"MR Green","year":"2015","unstructured":"Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci. 2015;112:E1116\u2013E1125.","journal-title":"Proc Natl Acad Sci"},{"key":"1124_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2010-03-272278","volume":"116","author":"MB Eide","year":"2010","unstructured":"Eide MB, Liest\u00f8l K, Lingj\u00e6rde OC, Hystad ME, Kresse SH, Meza-Zepeda L, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood. 2010;116:1489\u201397.","journal-title":"Blood"},{"key":"1124_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2016.175","volume":"31","author":"A Bouska","year":"2017","unstructured":"Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia. 2017;31:83\u201391.","journal-title":"Leukemia"},{"key":"1124_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2020.274258","volume":"107","author":"MCJ Ma","year":"2022","unstructured":"Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, et al. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022;107:690\u2013701.","journal-title":"Haematologica"},{"key":"1124_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.176.4.1137","volume":"176","author":"AD Zelenetz","year":"1992","unstructured":"Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med. 1992;176:1137\u201348.","journal-title":"J Exp Med"},{"key":"1124_CR17","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2008-08-174839","volume":"113","author":"E Carlotti","year":"2009","unstructured":"Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113:3553\u20137.","journal-title":"Blood"},{"key":"1124_CR18","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","volume":"82","author":"F Lo Coco","year":"1993","unstructured":"Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82:2289\u201395.","journal-title":"Blood"},{"key":"1124_CR19","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","volume":"82","author":"CA Sander","year":"1993","unstructured":"Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994\u20132004.","journal-title":"Blood"},{"key":"1124_CR20","doi-asserted-by":"publisher","first-page":"8886","DOI":"10.1073\/pnas.132253599","volume":"99","author":"IS Lossos","year":"2002","unstructured":"Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA. 2002;99:8886\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1124_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111\u201322.","journal-title":"Lancet Oncol"},{"key":"1124_CR22","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1182\/bloodadvances.2023010779","volume":"7","author":"DA Russler-Germain","year":"2023","unstructured":"Russler-Germain DA, Krysiak K, Ramirez C, Mosior M, Watkins MP, Gomez F, et al. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Adv. 2023;7:5524\u201339.","journal-title":"Blood Adv"},{"key":"1124_CR23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. N. Engl J Med. 2004;351:2159\u201369.","journal-title":"N. Engl J Med"},{"key":"1124_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19:549\u201361.","journal-title":"Lancet Oncol"},{"key":"1124_CR25","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1182\/blood-2009-02-202465","volume":"114","author":"AJ Gentles","year":"2009","unstructured":"Gentles AJ, Alizadeh AA, Lee S, Myklebust J, Shachaf C, Shahbaba B, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood. 2009;114:3158\u201366.","journal-title":"Blood"},{"key":"1124_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2013-07-512392","volume":"123","author":"M Brodtkorb","year":"2014","unstructured":"Brodtkorb M, Lingj\u00e6rde OC, Huse K, Tr\u00f8en G, Hystad ME, Hilden VI, et al. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood. 2014;123:1051\u20134.","journal-title":"Blood"},{"key":"1124_CR27","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.3324\/haematol.2018.209080","volume":"104","author":"CB Steen","year":"2019","unstructured":"Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, et al. A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. Haematologica. 2019;104:e460\u2013e464.","journal-title":"Haematologica"},{"key":"1124_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2022018719","volume":"142","author":"K Dreval","year":"2023","unstructured":"Dreval K, Hilton LK, Cruz M, Shaalan H, Ben-Neriah S, Boyle M, et al. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood. 2023;142:561\u201373.","journal-title":"Blood"},{"key":"1124_CR29","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/sj.leu.2404696","volume":"21","author":"J Fitzgibbon","year":"2007","unstructured":"Fitzgibbon J, Iqbal S, Davies A, O\u2019Shea D, Carlotti E, Chaplin T, et al. Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia. 2007;21:1514\u201320.","journal-title":"Leukemia"},{"key":"1124_CR30","doi-asserted-by":"publisher","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, et al. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med. 2016;13:e1002197.","journal-title":"PLoS Med"},{"key":"1124_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71\u201388.","journal-title":"Nat Rev Genet"},{"key":"1124_CR32","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41375-018-0043-y","volume":"32","author":"S Araf","year":"2018","unstructured":"Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, et al. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia. 2018;32:1261\u20135.","journal-title":"Leukemia"},{"key":"1124_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10001","volume":"6","author":"TS Alioto","year":"2015","unstructured":"Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun. 2015;6:10001.","journal-title":"Nat Commun"},{"key":"1124_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/nmeth.2642","volume":"10","author":"A Gonzalez-Perez","year":"2013","unstructured":"Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A, et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods. 2013;10:1081\u20132.","journal-title":"Nat Methods"},{"key":"1124_CR35","doi-asserted-by":"publisher","first-page":"14330","DOI":"10.1073\/pnas.1616440113","volume":"113","author":"CJ Tokheim","year":"2016","unstructured":"Tokheim CJ, Papadopoulos N, Kinzler KW, Vogelstein B, Karchin R. Evaluating the evaluation of cancer driver genes. Proc Natl Acad Sci USA. 2016;113:14330\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1124_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138.","journal-title":"Nature"},{"key":"1124_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11:396\u20138.","journal-title":"Nat Methods"},{"key":"1124_CR38","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1093\/annonc\/mdx517","volume":"28","author":"HX Dang","year":"2017","unstructured":"Dang HX, White BS, Foltz SM, Miller CA, Luo J, Fields RC, et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Ann Oncol. 2017;28:3076\u201382.","journal-title":"Ann Oncol"},{"key":"1124_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479\u201385.","journal-title":"Nature"},{"key":"1124_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.","journal-title":"Genome Biol"},{"key":"1124_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139.","journal-title":"Nat Methods"},{"key":"1124_CR42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AMSC Newman","year":"2019","unstructured":"Newman AMSC, Gentles AJ, Chaudhuri AA, Khodadoust MS, Esfahani MS, Steiner D, et al. High-throughput tissue dissection and cell purification with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"1124_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"1124_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, Ren W, Brodtkorb M, \u00d8stenstad B, Wahlin BE, Pan-Hammarstr\u00f6m Q, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188:259\u201367.","journal-title":"Br J Haematol"},{"key":"1124_CR45","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","volume":"3","author":"G Han","year":"2022","unstructured":"Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, et al. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022;3:428\u201343.","journal-title":"Blood Cancer Discov"},{"key":"1124_CR46","doi-asserted-by":"publisher","first-page":"E1282","DOI":"10.1073\/pnas.1215156110","volume":"110","author":"Z Zhu","year":"2013","unstructured":"Zhu Z, Li R, Li H, Zhou T, Davis RS. FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling. Proc Natl Acad Sci USA. 2013;110:E1282\u20131290.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1124_CR47","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","volume":"21","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21:1190\u20138.","journal-title":"Nat Med"},{"key":"1124_CR48","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","volume":"21","author":"A Ortega-Molina","year":"2015","unstructured":"Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199\u2013208.","journal-title":"Nat Med"},{"key":"1124_CR49","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ncb3597","volume":"19","author":"SJ Horton","year":"2017","unstructured":"Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, et al. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017;19:1093\u2013104.","journal-title":"Nat Cell Biol"},{"key":"1124_CR50","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","volume":"129","author":"I Garc\u00eda-Ram\u00edrez","year":"2017","unstructured":"Garc\u00eda-Ram\u00edrez I, Tadros S, Gonz\u00e1lez-Herrero I, Mart\u00edn-Lorenzo A, Rodr\u00edguez-Hern\u00e1ndez G, Moore D, et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood. 2017;129:2645\u201356.","journal-title":"Blood"},{"key":"1124_CR51","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Vlasevska S, Wells VA, Nataraj S, Holmes AB, Duval R, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov. 2017;7:322\u201337.","journal-title":"Cancer Discov"},{"key":"1124_CR52","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/2159-8290.CD-23-0111","volume":"13","author":"JG Schroers-Martin","year":"2023","unstructured":"Schroers-Martin JG, Soo J, Brisou G, Scherer F, Kurtz DM, Sworder BJ, et al. Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors. Cancer Discov. 2023;13:1310\u201323.","journal-title":"Cancer Discov"},{"key":"1124_CR53","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1182\/blood-2013-05-500264","volume":"123","author":"H Li","year":"2014","unstructured":"Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 2014;123:1487\u201398.","journal-title":"Blood"},{"key":"1124_CR54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrm.2017.94","volume":"19","author":"DV Fyodorov","year":"2018","unstructured":"Fyodorov DV, Zhou BR, Skoultchi AI, Bai Y. Emerging roles of linker histones in regulating chromatin structure and function. Nat Rev Mol Cell Biol. 2018;19:192\u2013206.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1124_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","volume":"589","author":"N Yusufova","year":"2021","unstructured":"Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589:299\u2013305.","journal-title":"Nature"},{"key":"1124_CR56","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hon.6_2630","volume":"S2","author":"J Okosun","year":"2019","unstructured":"Okosun J, B\u00f6d\u00f6r C, Batlevi C, N. Nagy N, Michot J, Schneider T, et al. EZH2 gain-of-function mutations are not associated with more favorable prognosis in relapsed\/refractory follicualr lymphoma (FL): A preliminary analysis of 590 patients. Hematological Oncol. 2019;S2:192\u20133.","journal-title":"Hematological Oncol"},{"key":"1124_CR57","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3324\/haematol.2013.094474","volume":"99","author":"E Mamessier","year":"2014","unstructured":"Mamessier E, Song JY, Eberle FC, Pack S, Drevet C, Chetaille B, et al. Early lesions of follicular lymphoma: a genetic perspective. Haematologica. 2014;99:481\u20138.","journal-title":"Haematologica"},{"key":"1124_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.32","volume":"7","author":"S Huet","year":"2017","unstructured":"Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7:e555.","journal-title":"Blood Cancer J"},{"key":"1124_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5599","volume":"11","author":"N Jain","year":"2019","unstructured":"Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, et al. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019;11:eaav5599.","journal-title":"Sci Transl Med"},{"key":"1124_CR60","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.4049\/jimmunol.177.10.6723","volume":"177","author":"I Wikstr\u00f6m","year":"2006","unstructured":"Wikstr\u00f6m I, Forssell J, Goncalves M, Colucci F, Holmberg D. E2-2 regulates the expansion of pro-B cells and follicular versus marginal zone decisions. J Immunol. 2006;177:6723\u20139.","journal-title":"J Immunol"},{"key":"1124_CR61","doi-asserted-by":"publisher","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048","volume":"29","author":"KA Blum","year":"2018","unstructured":"Blum KA, Abramson J, Maris M, Flinn I, Goy A, Mertz J, et al. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann Oncol. 2018;29:iii7\u2013iii9.","journal-title":"Ann Oncol"},{"key":"1124_CR62","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1182\/blood.2020009855","volume":"137","author":"S Haebe","year":"2021","unstructured":"Haebe S, Shree T, Sathe A, Day G, Czerwinski DK, Grimes SM, et al. Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood. 2021;137:2869\u201380.","journal-title":"Blood"},{"key":"1124_CR63","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.","journal-title":"Sci Transl Med"},{"key":"1124_CR64","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11523-024-01070-z","volume":"4","author":"NH Fowler","year":"2024","unstructured":"Fowler NH, Chavez JC, Riedell PA. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024;4:495\u2013510.","journal-title":"Target Oncol"},{"key":"1124_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103.","journal-title":"Lancet Oncol"},{"key":"1124_CR66","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med, 2024. Epub ahead of print.","DOI":"10.1038\/s41591-024-03175-4"},{"key":"1124_CR67","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"1124_CR68","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER 3rd, et al. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 2020;180:387\u2013402.","journal-title":"Cell"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01124-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01124-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01124-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:03:04Z","timestamp":1724756584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01124-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01124-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EK has served on the advisory boards of Celgene, Janssen and AbbVie, and has provided educational lectures for Celgene, Janssen, AbbVie and Astra Zeneca. OCL has served as a statistical advisor for Novartis and provided educational lectures for Nykode Therapeutics. HH has served on the advisory boards of Roche, Celgene, Nordic Nanovector, Novartis and Takeda and has provided educational lectures for Novartis. EBS owns stock in Nordic Nanovector and is a named inventor on a patent filed by the National Cancer Institute: \u201cMethods for selecting and treating lymphoma types\u201d licensed to NanoString Technologies; named inventor on a patent: \u201cEvaluation of mantle cell lymphoma and methods related thereof.\u201d All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}